Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
2010-11-1
pubmed:abstractText
Airway hyperresponsiveness and inflammation characterize the airways of individuals with asthma and chronic obstructive pulmonary disease (COPD). Hence, therapeutic approaches that attenuate such manifestations may offer promise in the management of these diseases. In the present study, we investigated whether a novel long-acting cholinergic antagonist, aclidinium bromide, modulates airway function and leukocyte trafficking in an Aspergillus fumigatus (Af)-induced murine model of asthma. Nebulized aclidinium (1 mg/ml) administration completely abrogated increases in methacholine-induced lung resistance in Af-exposed mice. Parallel assessment of dynamic compliance showed that aclidinium also completely restores methacholine-mediated decreases in naïve and Af-exposed mice. As evidenced by differential cell counts within bronchoalveolar lavage fluid, aclidinium also diminished (51±4%) Af-induced airway eosinophil numbers with no significant change in other immune cell types. Further assessment of cytokine and total protein levels in bronchoalveolar lavage fluid showed that aclidinium had little effect on IL-4 or IL-6 levels in either Af-exposed or naïve mice but markedly decreased total protein levels in bronchoalveolar lavage fluid. These data suggest that aclidinium, a selective muscarinic antagonist, not only acts as a bronchodilator but could also act as an anti-inflammatory agent with potential clinical benefits in the treatment of COPD and asthma.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1879-0712
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 Elsevier B.V. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
649
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
349-53
pubmed:dateRevised
2011-6-28
pubmed:meshHeading
pubmed-meshheading:20868661-Animals, pubmed-meshheading:20868661-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:20868661-Antigens, Fungal, pubmed-meshheading:20868661-Asthma, pubmed-meshheading:20868661-Bronchitis, pubmed-meshheading:20868661-Bronchoalveolar Lavage Fluid, pubmed-meshheading:20868661-Cell Count, pubmed-meshheading:20868661-Cholinergic Antagonists, pubmed-meshheading:20868661-Cytokines, pubmed-meshheading:20868661-Female, pubmed-meshheading:20868661-Inflammation, pubmed-meshheading:20868661-Leukocytes, pubmed-meshheading:20868661-Mice, pubmed-meshheading:20868661-Mice, Inbred BALB C, pubmed-meshheading:20868661-Pulmonary Disease, Chronic Obstructive, pubmed-meshheading:20868661-Pulmonary Eosinophilia, pubmed-meshheading:20868661-Respiratory Hypersensitivity, pubmed-meshheading:20868661-Respiratory System, pubmed-meshheading:20868661-Tropanes
pubmed:year
2010
pubmed:articleTitle
Aclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammation.
pubmed:affiliation
Airways Biology Initiative, Pulmonary, Allergy and Critical Care Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't